Session Abstract – PMWC 2022 Silicon Valley


The PMWC 2022 Clinical & Research Tools Showcase will provide a 15-minute time slot for selected companies in this space. The Clinical & Research Tools is a showcase for innovative technologies that are used for the analysis of genetic variation and function, helping to advance breakthroughs in genetic health, rare disease conditions on individuals of all ages, complex diseases and cancer care. Next-generation sequencing (NGS) and microarray technologies empower rapidly evolving genomic revolution.


Confirmed Presenting Companies:

 Session Chair Profile

M.D., Research Physician, National Human Genome Research Institute, NIH

Biography
Alexander Katz is the principal investigator of the Genomic Ascertainment Cohort (TGAC) a large-scale resource enabling predictive genomic research. Dr. Katz leads a team of clinicians and bioinformaticians in implementing clinical research at the NIH clinical center that aims to predict phenotype from genotype. TGAC’s approach includes aggregating genomic data from a phenotypically unselected population and formulating hypotheses based on genomic variants of interest rather than phenotypic traits of interest. Dr. Katz is board certified in clinical genetics, molecular genetics, and internal medicine, having completed a clinical fellowship at the National Human Genome Research Institute and residency at the University of Michigan. He also holds a bachelor’s degree from the University of Virginia and a master’s degree in human genetics from the University of Michigan.


Clinical & Research Tools Showcase:
National Human Genome Research Institute, NIH

National Human Genome Research Institute aims to advance genomic research at the National Institutes of Health.

Piloting Predictive Medicine with TGAC
The Genomic Ascertainment Cohort (TGAC) represents a paradigm-shifting approach to clinical genomics research. By starting with a genomic variant of interest in an individual and performing deep targeted phenotyping, we predict phenotype from genotype - which ultimately can transform genomic medicine.

 Speaker Profile

Ph.D., Chief Scientific Officer and Co-founder, Deep Lens

Biography
Dr. Bowen leverages his unique background in cancer research, software development, and strategy consulting to lead the team responsible for accelerating patient identification for cancer clinical trials. As a cancer researcher, he focused on pathological identification of tumor differentiation in breast cancers derived from p53, BRCA1/2, ATM and other mutations. More recently, he was a founding leader of the software innovation team at Fuse by Cardinal Health. Dr. Bowen was a Regents Scholar at the University of California, San Diego where he received his doctorate in Biomedical Sciences.


Clinical & Research Tools Showcase:
Deep Lens

Deep Lens matches prescreened patients to oncology clinical trials. We accelerate enrollment by coupling our AI platform VIPER with dedicated clinical research staff to decrease the burden on providers across our network of community oncology practices.

Improving Oncology Trial Accrual Rates with AI
The clinical trial landscape has changed. Clinical research teams face new challenges with increasingly complex precision oncology protocols. This showcase will cover how Deep Lens couples experienced clinical staff with AI-backed technology to accelerate patient accrual for precision studies.

 Speaker Profile

MA, International Economics; CEO, Deep 6 AI

Biography
Wout started his career as a diplomat in the Middle East before joining global management consulting firm, McKinsey & Company, serving a wide variety of industries across Asia. Next, Wout founded an extreme sports adventure company in Singapore and then spent five years in the high-stakes world of international security, growing and leading a 22,000-headcount organization across four continents into a $500M global player. Wout is a frequent speaker on artificial intelligence in healthcare and works closely with hospitals, pharma companies and research institutes on patient recruitment programs.


Clinical & Research Tools Showcase:
Deep 6 AI

Deep 6 AI finds more, better-matching patients for clinical trials in minutes rather than months. Using natural language processing to search unstructured data in medical records, our tool helps healthcare organizations and life sciences companies get life-saving cures to people more quickly.

Precision-matching: The Driver to High-performance Clinical Trials
Learn how a precision matching engine can drive performance throughout the entire clinical trial process. Wout will share the latest metrics & data, real world examples and a couple of surprising insights.

 Speaker Profile

Ph.D., CSO, Truckee Applied Genomics, LLC

Biography
Dr. Tian Yu is a Molecular Biologist experienced with life science/healthcare startups, currently focusing on leading products development in Truckee Applied Genomics and developing tools to improve the current covid testing by making it more affordable, more reliable, and keeping health care professionals safe from accidental viral exposures. Dr. Yu received her Ph.D. in biochemistry, molecular biology & cell biology in 2018. She has been published on topics such as epigenetic research for the interplay of RNA modifications and circular RNAs in the journal Cell Research. Before joining TAG, Dr. Yu has previously worked as an Assistant Core Director at the Single-Cell Sequencing Core, University of Nevada school of medicine, and then Bioelectronica as the lead biochemist where her research focused on developing life science tools for improving the antibody discovery workflow. The platform which she helped develop is now being placed in research labs across the globe.


Clinical & Research Tools Showcase:
Truckee Applied Genomics, LLC

Truckee Applied Genomics, LLC (TAG) is based in Reno Nevada and develops and manufactures patented reagents to improve molecular tests of tissues and pathogens.

New COVID-19 Surveillance Workflow With TAG-NGPM+
TAG-NGPM+ is the first specimen collection and transport media designed to improve safety for patients and lab staff by quickly inactivating virus while maintaining the sensitivity of molecular and rapid protein-based antigen assays. We propose a COVID-19 testing workflow that is designed to provide timely and accurate test results to patients and help with variant monitoring for effective transmission prevention and control.

 Speaker Profile

Ph.D., Co-Founder and Chief Scientific Officer, Cardea Bio

Biography
Dr. Kiana Aran is the Co-Founder and Chief Scientific Officer at Cardea Bio, an Associate Professor of Medical Diagnostics and Therapeutics at Keck Graduate Institute, a member of the Claremont Colleges, and a visiting Assistant Professor at the University of California, Berkeley. Dr. Aran also serves as a Consultant of Drug Delivery and Medical Diagnostics for the Bill & Melinda Gates Foundation. She received her undergraduate degree in electrical engineering from the City University of New York in 2007 and her Ph.D. in biomedical engineering from Rutgers University in 2012. She then continued her postdoctoral studies in bioengineering at the University of California Berkeley and was a recipient of the National Institutes of Health (NIH) postdoctoral training fellowship at the Buck Institute for Aging Research in 2015. Her research efforts focus on designing novel biosensing platforms, using 2D nanomaterials, for early disease diagnosis as well as utilizing biology as tech elements for a variety of biosensing applications. In addition to biosensing, she combines various engineering modules to develop tools to better understand the process of aging. Dr. Aran’s scientific vision is to explore the utility of nano-electronic systems to develop transformative and customizable platforms for multiomics applications and commercialization of these platform. Her efforts have been recognized within the scientific community by the Clinical OMICs 10 under 40 Award, Athena Pinnacle Award, and Nature Research Awards for Inspiring Women in Science: Scientific Achievement Category’s Overall Winner. Dr. Aran was also the recipient of the NSF Career Award to develop the next generation of electronic sensors.

Talk
All-electronic Infrastructure Leads Way to Real-time Multiomics
A critical challenge faced by systems biology is that multiomics is crippled by the current optical and static approaches all requiring numerous systems. Our all-electronic system unifies multiomics through direct and real-time capture of interactive streams of actionable multiomic data.


 Speaker Profile

Twist Biosciences

Biography
Speaker Twist Bioscience


Clinical & Research Tools Showcase:
Twist Biosciences

At Twist Bioscience, we work in service of people who are changing the world for the better. In fields such as medicine, agriculture, industrial chemicals and data storage, our unique silicon-based DNA Synthesis Platform provides precision at a scale that is otherwise unavailable to our customers.

 Speaker Profile

Ph.D., Director of Business Development, NuProbe, USA

Biography
Nicolas Garreau de Loubresse, Ph.D., serves as Director of Business Development for NuProbe, USA. Previously, he was a Research Fellow at the Wyss Institute at Harvard University and a Business Development Fellow at Harvard Office of Technology Development. He is also the co-founder of Urania Therapeutics and inventor of Urania’s core technologies. He published first-author articles in Science and Nature, and received competitive fellowships (EMBO, HFSP) and awards (AXA-French Academy of Science).


Clinical & Research Tools Showcase:
NuProbe

NuProbe is a cutting-edge genomics and molecular diagnostics company with revolutionary technologies to improve the analytical sensitivity of DNA disease biomarkers.

Rapid Custom Development Program for Oncology Translational Research
• Ultrasensitive PCR and NGS assays for tissue and liquid biopsy applications
• Proprietary enrichment technology to increase sensitivity and lower sequencing requirements
• Comprehensive solutions for mutation, CNV, and fusion analysis
• Custom assays with a pathway to clinical trial application and CDx

 Speaker Profile

Chief Executive Officer, LevitasBio

Biography
A highly technical life science executive with extensive business development and product marketing experience in the Life Sciences industry. Specific focus on the development of new technologies and commercialization with key experience in single-cell genomics, next-generation sequencing, gene expression, genotyping, and cell culture.


 Speaker Profile

Ph.D., Director of Business Development, Collaborative Drug Discovery

Biography
Whitney earned a PhD from UC Berkeley in 1996, developing a love for using computational and informatics tools to solve his in-the-lab chemistry challenges. Following roles at a number of Bay Area biotech startups as “the Med Chemist who also did computer stuff”, Whitney became a full-time Cheminformatics Scientist in 2003. A few years later he took a technical position at then-Accelrys, seeing our industry from a whole new perspective – the vendor side. In 2007, he transitioned to a sales role and has since held various regional and strategic positions at Accelrys, IDBS, Model N, and now Collaborative Dug Discovery. His responsibilities have included the sale and implementation of solutions across such highly diverse domains as cheminformatics, bioinformatics, GLP/GMP systems, business analytics, drug pricing, and revenue management. Whitney routinely engages with biotechs, big pharma, government, academic labs, and everyone in between to help solve their informatics, scientific, and business challenges.


 Speaker Profile

Ph.D., Co-Founder and CEO, Sano Genetics

Biography
Patrick Short is experienced in genomics research with a focus on large-scale genome sequencing projects and rare disorders. Prior to Sano Genetics, Patrick was previously at the Wellcome Trust Sanger Institute and the University of Cambridge.


Clinical & Research Tools Showcase:
Sano Genetics

Sano connects people with research in personalised medicine We provide access to free genome sequencing and analysis for research participants. You own your data and have full control over how it is used.

Enabling Precision Medicine Trials in Movement Disorders
To be successful, precision medicine trials must recruit patients informed by the patient’s unique genetic information. We will present a real-world example of a program in the movement disorder setting that successfully identified and tested patients for precision medicine trials.

 Speaker Profile

President and CEO, Engage Health, Inc.

Biography
As CEO and founder of Engage Health, Patti has helped define the rare disease space. Patti’s background in trial-enabling activities such as caregiver/patient identification, clinical trial recruitment, and health research prove useful to clients as they work to advance their programs in rare and complex conditions.


Clinical & Research Tools Showcase:
Engage Health

Engage Health’s team provides comprehensive services to further development of rare disease and precision medicine therapies. Sano Genetics connects people with research in personalized medicine.

Enabling Precision Medicine Trials in Movement Disorders
To be successful, precision medicine trials must recruit patients informed by the patient’s unique genetic information. We will present a real-world example of a program in the movement disorder setting that successfully identified and tested patients for precision medicine trials.

 Speaker Profile

MHA, Executive Vice President & General Manager, Clinical Services Business Unit, Guardian Research Network

Biography
Adam has improved clinical research by developing and leading strategies at a large CRO, a renowned site network, and a boutique CRO which he co-founded. At GRN, he leads clinical monitoring, data management, study feasibility and startup, patient eligibility, and study closeout, and is the primary account executive for GRN’s diagnostics clients. He also ensures GRN’s proprietary, HIPAA-compliant technology are fit-for-purpose to accelerate clinical trials.


Clinical & Research Tools Showcase:
Guardian Research Network

A nationwide hospital consortium, Guardian Research Network (GRN) is a 501(c)(3) nonprofit focused on accelerating cures for life-threatening diseases by bringing clinical trials to local communities.

Next-generation CRO: Marrying Contract Research & Real World Data

 Speaker Profile

Ph.D., Professor, National University of Singapore

Biography
Markus Wenk’s current research is determination of natural variation of circulating metabolites beyond well-known examples such as cholesterol. This knowledge will form a conceptual basis for integration of molecular phenotyping into precision health and medicine. In that context he and his team has initiated and are currently coordinating global trials aimed at technology harmonization and determination of biological reference ranges. Markus Wenk is a thought leader in mass spectrometry based lipidomics. He established the Singapore lipidomics incubator (SLING) and more recently the ‘NUS-Agilent Hub for translation and capture’, a $28 million facility for translation of biochemical innovation and techniques to clinical testing.


Clinical & Research Tools Showcase:
National University of Singapore

National University of Singapore, a leading global university, shaping the future.

Partnership Hub for Clinical Translation of Technology
I will introduce our partnership model from academic R&D laboratories with downstream reach to hospital-based laboratory medicine. Examples of biological variation of circulating blood metabolites will be provided together with its relevance for data-driven trials and clinical implementation.

 Speaker Profile

Global Marketing Development Manager, Digital Pathology, Epredia

Biography
Chris Coley, PA/HT(ASCP), has an extensive Anatomical Pathology background followed by various roles in sales and marketing for comprehensive product lines in the both clinical and research segments for over 25 years. His experiences enable him to implement market enhancing technologies that professionally align with Epredia’s mission and vision to improve lives by enhancing precision cancer diagnostics.


Clinical & Research Tools Showcase:
Epredia™

Epredia™ is a global precision cancer diagnostics company working to improve patient outcomes by providing groundbreaking technologies in the digital pathology and AI space.

Next Generation Laboratory Automation: TMA to Analysis
Epredia's presentation "Next-Generation Laboratory Automation: TMA to Analysis" will explore key products that are designed to take tedious manual processes and replace them with consistently accurate and time-saving devices, reducing one weeks' work into a single day.

 Speaker Profile

Chief Science Officer, simplSEQ

Biography
Brandon Young has 20 years of experience utilizing technology to improve testing and detection of genetic variation in human diseases. He was one of the early laboratory pioneers in microarray and gene sequencing projects in startup companies and large academic institutions. Brandon has helped design, build and run labs for a number of prestigious centers throughout the US, including Scripps Florida, Human Longevity Institute (HLI), and Avera McKennan.


Clinical & Research Tools Showcase:
simplSEQ

simplSEQ has developed a proprietary process that isolates and purifies nucleic acids from biological material including plasma samples. Our process is non-destructive, allowing for re-interrogation and multi-omic analysis from a single sample.

Democratizing Genomic Sequencing
By inventing a novel approach to sample preparation, simplSEQ makes NGS sample prep faster, less expensive with higher quality data than traditional methods. The presentation will include data and case studies illustrating how laboratories of all sizes and expertise levels will be able to perform genomic testing in-house.

 Speaker Profile

Inspirata®, Inc.

Biography
Speaker Inspirata


Clinical & Research Tools Showcase:
Inspirata®, Inc.

Inspirata®, Inc. helps patients fighting cancer, and the clinicians they trust, make every moment matter. Our comprehensive cancer informatics solutions bring together disparate data throughout the entire cancer care journey to drive informed decisions that improve survivorship.

 Speaker Profile

Ph.D., Associate Director of Product, NuProbe, USA

Biography
Alessandro Pinto, Ph.D., currently serves as Associate Director of Product at NuProbe. He received his Ph.D. in chemical engineering from the Rovira I Virgili University. Prior to joining NuProbe, he worked as a Postdoctoral Researcher at University of Basque Country and a Research Scientist at Rice University, with a focus on cancer diagnostics and next-generation sequencing technologies. His work in academia led to 12 peer-reviewed publications, 4 patent families, and 2 book chapters.


Clinical & Research Tools Showcase:
NuProbe

NuProbe is a cutting-edge genomics and molecular diagnostics company with revolutionary technologies to improve the analytical sensitivity of DNA disease biomarkers.

Rapid Custom Development Program for Oncology Translational Research
• Ultrasensitive PCR and NGS assays for tissue and liquid biopsy applications
• Proprietary enrichment technology to increase sensitivity and lower sequencing requirements
• Comprehensive solutions for mutation, CNV, and fusion analysis
• Custom assays with a pathway to clinical trial application and CDx

 Speaker Profile

Ph.D., CSO, Notable Labs

Biography
Joe has been working in biotech for nearly 20 years and was previously Executive Director of the University of California Drug Discovery Consortium (UC-DDC). A pharmacologist by training, Joe has spent the majority of his biotechnology industry career focused on building teams and organizations primarily focused on developing small molecule and biologic therapeutics from bench studies through to Phase II clinical trials at companies including BriaCell Therapeutics, OncoCyte and Cell Targeting, where he served in CEO/CTO roles.


Clinical & Research Tools Showcase:
Notable Labs

Notable is a clinical-stage platform therapeutics company designing and delivering predictive precision medicines, a new class of medicines. Notable aims to revolutionize the way in which patients seek and receive treatments that work best for them – patient by patient, and cancer by cancer.

Advancing Predictive Precision Medicine Using Functional Approach
Although genomic- and biomarker-driven precision medicine strategies have improved outcomes for those patients with certain disease characteristics, most cancer patients lack actionable mutations or biomarkers. Predictive precision medicine utilizing a functional, ex vivo approach offers hope for those patients.

 Speaker Profile

Ph.D., Chief Science Officer, Fluidigm Corporation

Biography
Dr. Quong is the Chief Science Officer, and he serves as liaison and bridge to the research community, identifying opportunities to address unmet needs in human health. He is the primary point of contact to pharma industry consortia and other avenues of global collaboration and plays a key role on establishing product roadmaps and broad product development priorities as well as potential partnership, licensing, and acquisition opportunities. Previously he was the Director of Strategic Scientific Initiatives and Partnerships at the Frederick National Laboratory for Cancer Research and was a faculty member in the Department of Cancer Biology at Thomas Jefferson University and the Department of Oncology at Georgetown University. His research focused on systems biology approaches to understanding mechanisms of resistance to treatment of breast cancer and biomarkers of response. He has published extensively and served on the editorial boards of Cancer Research and The American Journal of Pathology.


Clinical & Research Tools Showcase:
Fluidigm

Fluidigm (NASDAQ:FLDM) is an industry-leading biotechnology tools provider with a vision to improve life through comprehensive health insight. We focus on the most pressing needs in translational and clinical research, including cancer, immunology, and immunotherapy. Using proprietary CyTOF® and microfluidics technologies, we develop, manufacture, and market multi-omic solutions to drive meaningful insights in health and disease, identify biomarkers to inform decisions, and accelerate the development of more effective therapies. Our customers are leading academic, government, pharmaceutical, biotechnology, and plant and animal research laboratories worldwide. Together with them, we strive to increase the quality of life for all.

Reimagining High-content Immune Profiling for Clinical Research
Time and samples are precious commodities when it comes to clinical research, particularly for large cohorts.  Learn about the advantages of easy workflows for high-parameter assays, minimal sample volumes and automated analysis with Fluidigm’s CyTOF XT® and immune profiling solutions.

 Speaker Profile

Head of Corporate and Research Development, Sengenics

Biography
Nurul is the Head of Corporate and Research Development at Sengenics Corporation Pte Ltd, a functional proteomics company that leverages its patented KREX™ technology for production of full-length, correctly folded and functional proteins. Sengenics currently has partnerships with 9 out of the top 20 pharma to co-develop companion diagnostic tests for autoimmune and cancer immunotherapy drugs. Her previous experience in managing KREX operations has enabled her to take on her current role which focuses on accelerating KREX’s R&D pipeline towards FDA approval and commercialisation.


Clinical & Research Tools Showcase:
Sengenics

Sengenics is a functional proteomics company that leverages its patented KREX technology for stratification of patients undergoing treatment with autoimmune or cancer drugs into responders, non-responders and those exhibiting irAEs. KREX can also be used to identify autoantibody biomarkers for early diagnosis of cancer, autoimmune or neurodegenerative conditions.